Evidence map›Paper›PMID 37950707›Full record

ArticleAntioxidants & redox signaling2024

Isopentyl-Deoxynboquinone Induces Mitochondrial Dysfunction and G2/M Phase Cell Cycle Arrest to Selectively Kill

Lingxiang Jiang, Yingchun Liu, Soumya Tumbath, Matthew W Boudreau, Lindsay E Chatkewitz, Jiangwei Wang, Xiaolin Su, Kashif Rafiq Zahid, Katherine Li, Yaomin Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants & redox signaling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Hesperetin induces apoptosis in lung squamous carcinoma cells via GInternational journal of molecular medicine · 2025
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lingxiang JiangDepartment of Radiation Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Yingchun LiuDepartment of Radiation Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Soumya TumbathDepartment of Radiation Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Matthew W BoudreauDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Lindsay E ChatkewitzDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Jiangwei WangDepartment of Radiation Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Xiaolin SuDepartment of Biochemistry and Molecular Biology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kashif Rafiq ZahidDepartment of Radiation Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Katherine LiDepartment of Radiation Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Yaomin ChenIndiana University Health Pathology Laboratory, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kai YangDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Paul J HergenrotherDepartment of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Xiumei HuangDepartment of Radiation Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-7306-0288

Funding

Training Program at the Chemistry Biology InterfaceT32GM136629 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Paul Hergenrother · 2020 to 2026
$4.5M
Targeting NQO1+ tumor to trigger innate and adaptive immunityR01CA240952 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI HUANG, XIUMEI · 2020 to 2024
$2.1M
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancerR01CA221158 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, XIUMEI, MOTEA, EDWARD AYSON · 2017 to 2022
$1.9M
Targeted Therapy for Head and Neck CancerR01DE026836 · NIDCR · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI HERGENROTHER, PAUL · 2018 to 2022
$1.8M
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugsR01CA224493 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI HUANG, XIUMEI · 2018 to 2022
$1.8M
Targeting Oncogenic Drivers in CancerF99CA253731 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI BOUDREAU, MATTHEW W · 2020 to 2021
$93k
NCI NIH HHS F99 CA253731NCI NIH HHS R01 CA221158NCI NIH HHS R01 CA224493NCI NIH HHS R01 CA240952NIGMS NIH HHS T32 GM136629
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

G2 Phase Cell Cycle CheckpointsMitochondriaNAD(P)H Dehydrogenase (Quinone)Pancreatic NeoplasmsAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationHumansMiceQuinonesReactive Oxygen SpeciesXenograft Model Antitumor AssaysAntineoplastic AgentsdeoxynyboquinoneNAD(P)H Dehydrogenase (Quinone)NQO1 protein, humanQuinonesReactive Oxygen SpeciesapoptosisDNA damagemitochondrial dysfunctionNAD+/ATP lossNQO1PARP1 hyperactivationprogrammed necrosisROS formation

Identifiers

PMID37950707
PMCPMC11321107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.